Modality
mAb
MOA
FXIai
Target
EZH2
Pathway
Sphingolipid
AsthmaPV
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
~Dec 2020
→ ~Mar 2022
Phase 2
Jun 2022
→ Sep 2027
Phase 2Current
NCT03799388
160 pts·Asthma
2022-06→2026-05·Terminated
NCT08619940
1,663 pts·Asthma
2023-08→2027-09·Not yet recruiting
1,823 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-051mo awayPh3 Readout· Asthma
2027-09-221.5y awayPh3 Readout· Asthma
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2/3
Termina…
P2/3
Not yet…
Catalysts
Ph3 Readout
2026-05-05 · 1mo away
Asthma
Ph3 Readout
2027-09-22 · 1.5y away
Asthma
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03799388 | Phase 2/3 | Asthma | Terminated | 160 | LiverFat |
| NCT08619940 | Phase 2/3 | Asthma | Not yet recr... | 1663 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Pexanesiran | United Therapeutics | Phase 1 | BCMA | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 |